Literature DB >> 26722164

Coccidioidomycosis with diffuse miliary pneumonia.

David Sotello1, Marcella Rivas1, Audra Fuller1, Tashfeen Mahmood1, Menfil Orellana-Barrios1, Kenneth Nugent1.   

Abstract

Coccidioidomycosis is a well-known infection in the southwestern United States, and its occurrence is becoming more frequent in endemic areas. This disease can have a significant economic and medical impact; therefore, accurate diagnosis is crucial. In conjunction with patient symptoms, residence in or travel to an endemic area is essential for diagnosis. Diagnosis is usually made with serology, culture, or biopsy and confirmed with DNA probe technology. Pulmonary disease is the most common presentation and is seen in almost 95% of all cases. One-half to two-thirds of all Coccidioides infections are asymptomatic or subclinical. Most pulmonary infections are self-limited and do not require treatment except in special populations. When treatment is warranted, itraconazole and fluconazole are frequently used. Diffuse miliary pneumonia is uncommon and is especially rare in immunocompetent patients. Herein we describe a rare presentation of miliary coccidioidomycosis in a nonimmunocompromised patient.

Entities:  

Year:  2016        PMID: 26722164      PMCID: PMC4677849          DOI: 10.1080/08998280.2016.11929351

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  10 in total

Review 1.  Pulmonary coccidioidomycosis.

Authors:  George R Thompson
Journal:  Semin Respir Crit Care Med       Date:  2011-12-13       Impact factor: 3.119

Review 2.  Coccidioidomycosis.

Authors:  John N Galgiani; Neil M Ampel; Janis E Blair; Antonino Catanzaro; Royce H Johnson; David A Stevens; Paul L Williams
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

Review 3.  Coccidioidomycosis: a review of recent advances.

Authors:  Neil M Ampel
Journal:  Clin Chest Med       Date:  2009-06       Impact factor: 2.878

4.  Miliary coccidioidomycosis in the immunocompetent.

Authors:  E L Arsura; W B Kilgore
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

5.  Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group.

Authors:  J N Galgiani; A Catanzaro; G A Cloud; R H Johnson; P L Williams; L F Mirels; F Nassar; J E Lutz; D A Stevens; P K Sharkey; V R Singh; R A Larsen; K L Delgado; C Flanigan; M G Rinaldi
Journal:  Ann Intern Med       Date:  2000-11-07       Impact factor: 25.391

Review 6.  Update on the diagnosis of pulmonary coccidioidomycosis.

Authors:  Joshua Malo; Carmen Luraschi-Monjagatta; Donna M Wolk; R Thompson; Chadi A Hage; Kenneth S Knox
Journal:  Ann Am Thorac Soc       Date:  2014-02

Review 7.  Chapter 2: coccidioidomycosis.

Authors:  Antônio de Deus Filho
Journal:  J Bras Pneumol       Date:  2009-09       Impact factor: 2.624

Review 8.  Coccidioidomycosis.

Authors:  James M Parish; Janis E Blair
Journal:  Mayo Clin Proc       Date:  2008-03       Impact factor: 7.616

Review 9.  The public health impact of coccidioidomycosis in Arizona and California.

Authors:  Richard F Hector; George W Rutherford; Clarisse A Tsang; Laura M Erhart; Orion McCotter; Shoana M Anderson; Kenneth Komatsu; Farzaneh Tabnak; Duc J Vugia; Ying Yang; John N Galgiani
Journal:  Int J Environ Res Public Health       Date:  2011-04-15       Impact factor: 3.390

10.  Increase in reported coccidioidomycosis--United States, 1998-2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-03-29       Impact factor: 17.586

  10 in total
  2 in total

1.  Miliary Histoplasmosis in a Patient with Rheumatoid Arthritis.

Authors:  Jessica Lum; Maheen Z Abidi; Bruce McCollister; Andrés F Henao-Martínez
Journal:  Case Rep Med       Date:  2018-04-16

2.  Concomitant Central Nervous System Toxoplasmosis and Seronegative Disseminated Coccidioidomycosis in a Newly Diagnosed Acquired Immune Deficiency Syndrome Patient.

Authors:  Michael Valdez; Leila Moosavi; Arash Heidari
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.